07:30-08:30 Registrations

08:30-09:00 Opening Ceremony

**Keynote Forum**

09:00-09:05 Introduction

*Title: DNA immunization to prime the high quality antigen-specific B cell responses – a powerful pathway to induce protective antibodies*

Shan Lu, University of Massachusetts Medical School, USA

09:05-09:45

*Title: Pan-Lassa fever vaccine for prevention and post-challenge applications*

Igor S Lukashevich, University of Louisville, USA

09:45-10:25

*Title: Altered vaccine immune responses to different Toll-Like receptor activators*

Kei Amemiya, US Army Medical Research Institute of Infectious Diseases, USA

**Group Photo**

Networking & Refreshments Break 10:25-10:45 @ Foyer

10:45-11:25

*Title: Addressing challenges and solution for using T cell based assays for immune monitoring*

Magdalena Tary-Lehmann, Cellular Technology Limited, USA

10:45-11:05

*Title: Plant virus nanoparticles: New applications for developing countries*

Kathleen Hefferon, Cornell University, USA

11:05-11:25

*Title: Stability modeling to predict vaccine shelf-life and evaluate impact of temperature excursions from the “cold chain”*

Didier Clenet, Sanofi-Pasteur, France

11:25-11:50

*Title: Multi-epitope fusion antigen (MEFA), novel technology for structural vaccinology*

Weiping Zhang, Kansas State University, USA

11:50-12:15

*Title: Singapore Immunology Network’s clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials*

Brian Abel, A*STAR, Singapore

12:15-12:40

*Title: Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication: Underappreciated role of location and immunodominance in vaccination against chronic infection*

Peter Johannes Holst, University of Copenhagen, Denmark

Sessions: Childhood Vaccines | Vaccines against Vector-borne Diseases

Session Chair: Brian Abel, A*STAR, Singapore

14:45-15:10

*Title: Vaccination coverage cluster surveys in Middle Dreib–Akkar, Lebanon: Comparison of vaccination coverage in children aged 12-59 months pre- and post-vaccination campaign*

Randa Hamadeh, Ministry of Public Health, Lebanon

15:10-15:35

*Title: Responding to the threat of emergent infectious diseases*

Klaus Schwamborn, Valneva SE, France

Lunch Break: 12:40-13:30 @ N Café
Title: Polio outbreak stopped in the Middle East, efforts are still needed  
Randa Hamadeh, Ministry of Public Health, Lebanon

Title: Modified MHCII associated invariant chain induces increased antibody responses against *Plasmodium falciparum* antigens after adenoviral vaccination  
Cyrielle Fougeroux, Copenhagen University, Denmark

Title: Oil-based adjuvants and intradermal vaccine delivery: Th1 vs. Th2 response  
Zrinka Oreskovic, Veterinary Research Institute, Czech Republic

Title: Bovine herpesvirus type 4-BAC as an attractive viral vector for vaccination and gene therapy  
Touraj Aligholipour Farzani, Ankara University, Turkey

Title: Live, attenuated vaccines in animal health: VitamFero’s products and a few others  
Pascal Breton, VitamFero, France

Title: Pneumococcal polysaccharide vaccines for elderly: Here, there and everywhere  
Ger T Rijkers, University College Roosevelt, Netherlands

Title: Exploiting defects of type I interferon response in tumor cells for oncolytic immunotherapy with attenuated measles virus  
Jean-François Fonteneau, University of Nantes, France

Title: Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors  
Karola Rittner, Transgene SA, France

Title: Biogenic selenium nanoparticles can shift the immune response of breast cancer bearing mice toward Th1 pattern  
Mohammad Hossein Yazdi, Tehran University of Medical Sciences, Iran

Title: Recombinant lapidated subunit vaccines induce robust immunity against all four serotypes of dengue virus  
Hsin-Wei Chen, National Health Research Institutes, Taiwan

Title: Therapeutic vaccination in chronic infectious diseases: The place of vectored vaccines  
Geneviève Inchauspé, Transgene SA, France

Title: A toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population  
Chih-Hsiang Leng, National Health Research Institutes, Taiwan

Title: Development of innovative vaccines by the combination of novel technologies  
Fumihiko Takeshita, Daiichi Sankyo Co. Ltd., Japan
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:55-15:20</td>
<td>Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and ameliorates vaccine efficacy</td>
<td>Ming-Hsi Huang, National Health Research Institutes, Taiwan</td>
</tr>
<tr>
<td>15:20-15:45</td>
<td>Kinetics of myeloid derived suppressor cells (MDSC) and their effect on vaccine-specific responses during the first year of life</td>
<td>Ana Gervassi, Center for Infectious Disease Research, USA</td>
</tr>
</tbody>
</table>

**Panel Discussion**

**Poster Presentations: 16:05-16:30 @ Meeting Hall**

| EVACC 01 | Development of a peptide vaccine platform for brain tumor immunotherapy that incorporates adjuvant CD27 stimulation for enhanced T cell immunity | Katherine Riccione, Duke University, USA |
| EVACC 02 | Clostridium difficile flagellin FliC as an adjuvant to induce a protective gut mucosal immune response | Jean-François Bruxelle, University of Paris-Su, France |
| EVACC 03 | LPS/Endotoxins molecular diversity impacting vaccines and adjuvants activities and toxicity | Alexey Novokiv, LPS-Biosciences, France |
| EVACC 04 | Construction for minimal positive conditions for the safety of brain from vaccines to be supplied quickly at widespread epidemics | Sun Shin Yi, Soonchunhyang University, Republic of Korea |
| EVACC 05 | Development and preclinical evaluation of 15 pneumococcal polysaccharide CRM197 conjugate candidate vaccines in mouse model | Huyen T Pham, Konkuk University, South Korea |
| EVACC 06 | Study for establishment of 1st National Reference Standard for cell-derived Japanese encephalitis vaccine (Beijing strain) | Ji Young Hong, National Institute of Food and Drug Safety Evaluation, South Korea |
| EVACC 07 | Flavivirus nonstructural protein 1-based recombinant vaccines | Ching-Len Liao, National Health Research Institutes, Taiwan |
| EVACC 08 | Heterologous prime-boost tetravalent dengue vaccine strategy elicits complete protection against DENV-2 in non-human primates | Chutitorn Ketloy, Chulalongkorn University, Thailand |

**Awards for Poster Presentations**

**Day 3 | June 21, 2017 | Wednesday**

Extended Networking & Lunch 12:30-13:20 @ N Café